Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

NCT03905525 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

273

Enrollment

INDUSTRY

Sponsor class

Conditions

Sjögren Syndrome

Interventions

DRUG: CFZ533
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals